ES2185658T3 - Vacuna para la otitis media. - Google Patents

Vacuna para la otitis media.

Info

Publication number
ES2185658T3
ES2185658T3 ES94922428T ES94922428T ES2185658T3 ES 2185658 T3 ES2185658 T3 ES 2185658T3 ES 94922428 T ES94922428 T ES 94922428T ES 94922428 T ES94922428 T ES 94922428T ES 2185658 T3 ES2185658 T3 ES 2185658T3
Authority
ES
Spain
Prior art keywords
fimbrine
dna
vaccine
otitis
codifies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94922428T
Other languages
English (en)
Inventor
Pappachan E Kolattukudy
Lauren O Bakaletz
Tatiana Sirakova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University Research Foundation
Original Assignee
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation
Application granted granted Critical
Publication of ES2185658T3 publication Critical patent/ES2185658T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE HA DESCUBIERTO QUE UNA VACUNA QUE COMPRENDE FIMBRINA, UNA PROTEINA FILAMENTOSA DERIVADA DE LOS APENDICES SUPERFICIALES BACTERIANOS DEL "HAEMOPHILUS INFLUENZAE" ES UTIL EN EL ESTUDIO, LA PREVENCION O LA REDUCCION DE LA SEVERIDAD DE LA OTITIS MEDIA. TAMBIEN SE HA DETERMINADO LA SECUENCIA DE GENES DEL DNA QUE CODIFICA LA FIMBRINA Y LA SECUENCIA DE AMINOACIDO DE LA FIMBRINA. TAMBIEN SE HAN DESARROLLADO VECTORES QUE CONTIENEN EL DNA QUE CODIFICA LA FIMBRINA, Y TRANSFORMANTES QUE HAN SIDO PREPARADOS Y QUE CONTIENEN TALES VECTORES Y QUE EXPRESAN DICHO DNA Y SUMINISTRAN UNA FUENTE DE FIMBRINA PURA.
ES94922428T 1993-05-18 1994-05-12 Vacuna para la otitis media. Expired - Lifetime ES2185658T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6544293A 1993-05-18 1993-05-18

Publications (1)

Publication Number Publication Date
ES2185658T3 true ES2185658T3 (es) 2003-05-01

Family

ID=22062752

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94922428T Expired - Lifetime ES2185658T3 (es) 1993-05-18 1994-05-12 Vacuna para la otitis media.

Country Status (9)

Country Link
US (3) US5766608A (es)
EP (2) EP0699076B1 (es)
JP (1) JP3429313B2 (es)
AT (1) ATE226831T1 (es)
DE (1) DE69431624T2 (es)
DK (1) DK0699076T3 (es)
ES (1) ES2185658T3 (es)
PT (1) PT699076E (es)
WO (1) WO1994026304A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3429313B2 (ja) 1993-05-18 2003-07-22 オハイオ・ステイト・リサーチ・ファウンデーション 中耳炎ワクチン
JPH09500013A (ja) * 1993-06-01 1997-01-07 ライフ・テクノロジーズ・インコーポレイテッド カチオン性脂質による遺伝子免疫
US5770213A (en) 1994-05-05 1998-06-23 American Cyanamid Company Purified nontypable haemophilus influenzae P5 protein as a vaccine for nontypable haemophilus influenzae infection
US5843464A (en) * 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
GB9812613D0 (en) * 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
CA2350882C (en) 1998-11-12 2011-02-22 Life Technologies Corporation Transfection reagents
CA2366152A1 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0117762D0 (en) * 2001-07-20 2001-09-12 Glaxosmithkline Biolog Sa Novel compounds
CN1674933B (zh) 2002-08-02 2012-09-26 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
CA2503871C (en) 2002-11-01 2012-12-11 Glaxosmithkline Biologicals S.A. An immunogenic composition for generating an immune response against polio virus
AU2004277342B2 (en) 2003-10-02 2010-12-16 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
WO2007008527A2 (en) * 2005-07-08 2007-01-18 Children's Hospital Inc. Chimeric vaccine for haemophilus influenzae-induced disease
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
JP5792920B2 (ja) 2005-12-22 2015-10-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
MX2008009280A (es) 2006-01-17 2008-12-12 Arne Forsgren Una nueva proteina de haemophilus influenzae expuesta en la superficie (proteina e; pe).
EA200901578A1 (ru) 2007-06-26 2010-08-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
US9127306B2 (en) 2008-02-15 2015-09-08 Life Technologies Corporation Methods and apparatuses for nucleic acid shearing by sonication
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
EP2544714A1 (en) 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Vaccine composition
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
WO2012170356A1 (en) 2011-06-04 2012-12-13 Rochester General Hospital Research Institute Compositions and methods related to p6 of haemophilus influenzae
EP2964257B1 (en) 2013-03-08 2024-10-09 Research Institute at Nationwide Children's Hospital Transcutaneous dosage formulation
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB2600652B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel compositions
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
BR112021000965A2 (pt) 2018-08-07 2021-04-27 Glaxosmithkline Biologicals S.A. processos e vacinas
EP3886901A1 (en) 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
WO2020245207A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888170A (en) * 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
DK219084D0 (da) * 1984-05-02 1984-05-02 Frederik Carl Peter Lindberg Antigen
US5110908A (en) * 1986-12-31 1992-05-05 Praxis Biologics, Inc. Haemophilus influenzae peptides and proteins
JP3429313B2 (ja) 1993-05-18 2003-07-22 オハイオ・ステイト・リサーチ・ファウンデーション 中耳炎ワクチン

Also Published As

Publication number Publication date
EP0699076A1 (en) 1996-03-06
ATE226831T1 (de) 2002-11-15
DE69431624T2 (de) 2003-07-10
WO1994026304A1 (en) 1994-11-24
JP3429313B2 (ja) 2003-07-22
EP1300156A2 (en) 2003-04-09
PT699076E (pt) 2003-03-31
US6030626A (en) 2000-02-29
JPH09500104A (ja) 1997-01-07
US6562349B1 (en) 2003-05-13
DE69431624D1 (de) 2002-12-05
DK0699076T3 (da) 2003-03-03
US5766608A (en) 1998-06-16
EP0699076B1 (en) 2002-10-30
EP1300156A3 (en) 2003-05-07
EP0699076A4 (en) 1999-09-08

Similar Documents

Publication Publication Date Title
DE69431624D1 (de) Impfstoff gegen mittelohrentzündung
WO1998027204A3 (en) AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors
ATE177757T1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
GB9108652D0 (en) Immunoreactive compounds
GR3026658T3 (en) Hydrazino-type radionuclide chelators having an n 3?s configuration
ES2177476T1 (es) Genes de corynebacterium glutamicum que codifican proteinas implicadas en la sintesis de la membrana y el transporte a traves de la membrana.
ES2176128T1 (es) Genes de corynebacterium glutamicum que codifican proteinas implicadas en la homeostasis y la adaptacion.
NO965487D0 (no) Optiske hvitemidler
AU7528894A (en) Hydrazino-type n2s2 chelators
EP0610517A4 (en) Dna coding for decarbamylase improved in thermostability and use thereof.
EP0982988A4 (en) IN KEY PURE ZONULIN AS A PHYSIOLOGICAL MODULATOR OF "TIGHT JUNCTIONS" IN MAMMALS
NO940736D0 (no) DNA sekvenser som koder for gelonin polypeptid
EP0754229A1 (en) Alfamin: a human serum albumin-like protein
BR9811850A (pt) Expressão recombinante de peptìdeo c de insulina
HUP0104825A2 (hu) Gének, fehérjék és alkalmazásuk
IL122606A (en) (S)-hydroxa-nitrile-lyase
HUT77029A (hu) A GAP-protein SH3 doménjéhez kötődni képes peptidek, ezeket kódoló nukleotidszekvenciák és előállításuk és alkalmazásuk
DK0561846T3 (da) 4,5-dihydroxy- og 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracencarboxylsyre-dicarbonater og -urethaner med terapeutisk virkning
DK0990703T3 (da) Nyt polypeptid, DNA, som koder herfor, samt anvendelse heraf
ATE210184T1 (de) Ungespleisste varianten des gp350/220
ATE214427T1 (de) Chimäre msp und daf proteine mit einem telloberflächenlokalisierendem domän
DK0789764T3 (da) Ny familie af proteaseinhibitorer og andre biologisk aktive substanser
DK0946590T3 (da) Dihydroxypropylcysteinpeptid og middel, der indeholder dette peptid
YU200091A (sh) Delecioni mutanti ahasarezistentni na herbicide
WO1992011367A3 (en) Lipid receptors for microorganisms and corresponding adhesins, dna sequences encoding adhesins, and use thereof